Literature DB >> 29603034

Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 μg.

L M Koeth1, E Matuschek2, G Kahlmeter2, G Stone3.   

Abstract

Ceftazidime-avibactam disk studies were performed for disk mass selection and for establishing EUCAST quality control ranges and zone diameter breakpoints. The disk mass study included disk diffusion testing with ceftazidime-avibactam 10-4 and 10-6 μg disks and broth microdilution MIC testing for challenge set of 94 Enterobacteriaceae and 45 Pseudomonas aeruginosa. EUCAST SOP 9.0-based QC and MIC-disk correlations studies were followed for development of ceftazidime-avibactam 10-4 μg ranges for Escherichia coli ATCC 25922, P. aeruginosa ATCC 27583, and Klebsiella pneumoniae ATCC 700603 and for zone diameter breakpoint determination. The ceftazidime-avibactam 10-4 and 10-6 μg disks performed similar in comparison to broth microdilution, with zones ≤ 14 mm for all resistant strains. The 10-4 μg disk was selected and used in QC and breakpoint studies. There was minimal variation of ceftazidime-avibactam 10-4 μg QC study results between disks, media, and sites. The QC ranges were within 7 mm for all strains. The zone diameter breakpoint study demonstrated good correlation of MIC and disk results. The established zone diameter breakpoints resulted in false susceptible rates of 1.6 and 4.0% for Enterobacteriaceae and P. aeruginosa. EUCAST selected the ceftazidime-avibactam 10-4 μg disk and established QC ranges for E. coli 25922 of 24-30 mm, P. aeruginosa ATCC 27853 of 21-27 mm, and K. pneumoniae ATCC 700603 of 18-24 mm. The zone diameter breakpoints that correlated best with the MIC breakpoints of susceptible ≤ 8 mg/L and resistant > 8 mg/L were Enterobacteriaceae (S ≥ 13, R < 13 mm) and P. aeruginosa (S ≥ 17, R < 17 mm).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29603034     DOI: 10.1007/s10096-018-3215-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

1.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

2.  Analysis of MIC and Disk Diffusion Testing Variables for Gepotidacin and Comparator Agents against Select Bacterial Pathogens.

Authors:  L M Koeth; J M DiFranco-Fisher; N E Scangarella-Oman; L A Miller
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

3.  Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.

Authors:  A M Nilius; J M Beyer; R K Flamm; S K Tanaka
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

4.  Effect of zinc concentration in Mueller-Hinton agar on susceptibility of Pseudomonas aeruginosa to imipenem.

Authors:  J S Daly; R A Dodge; R H Glew; D T Soja; B A DeLuca; S Hebert
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

5.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

6.  Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura Koeth; Mendel E Singer; Caryn E Good
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  Effect of cation content of agar on the activity of gentamicin, tobramycin, and amikacin against Pseudomonas aeruginosa.

Authors:  J A Washington; R J Snyder; P C Kohner; C G Wiltse; D M Ilstrup; J T McCall
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

  7 in total
  1 in total

1.  Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.

Authors:  E Wenzler; M Lee; T J Wu; K A Meyer; R K Shields; M H Nguyen; C J Clancy; R M Humphries; A T Harrington
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.